PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708)

BACKGROUND: The indoleamine 2,3-dioxygenase (IDO) pathway is a natural immune-checkpoint mechanism often exploited by tumors to escape anti-tumor immunity. Small-molecule IDO pathway inhibitor drugs, such as indoximod, are in multiple trials for adults. Combining indoximod immunotherapy with re-irra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Johnson, Theodore S, Aguilera, Dolly, Al-Basheer, Ahmad, Cooksey, Raven M, Eaton, Bree R, Esiashvili, Natia, Firat, Selim, Fiveash, John B, Foreman, Nicholas, Fridlyand, Diana, Friedman, Gregory K, Giller, Cole A, Grosshans, David R, Heger, Ian M, Kelly, Michael, Kennedy, Eugene P, Knipstein, Jeffrey, Kolhe, Ravindra B, Liu, Arthur K, Martin, William, Mourad, Waleed F, Pacholczyk, Rafal, Parker, Rebecca, Rojiani, Amyn M, Sadek, Ramses F, Thornton, Allan, Vahanian, Nicholas N, MacDonald, Tobey, Munn, David
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693127/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.750
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados